ALK and glioblastoma: In conclusion, in this phase Ib study, the inhibition of c-MET and ALK through the addition of crizotinib to standard RT and TMZ was safe and resulted in a highly promising efficacy for newly diagnosed GBM, granting further investigation on the combination of ALK/MET inhibitors with chemoradiotherapy.